HIV / AIDS

The panel discusses the importance of starting HIV treatment early after diagnosis and offers advice to clinical providers.

Experts on the treatment of HIV discuss how they talk with their patients about adverse effects associated with HIV regimens.

The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

Efforts among organizations aim to develop innovative vaccine candidates and advancements in the global fight against HIV.

Focusing on the evolving treatment paradigms for HIV, the panel reviews guideline recommendations for initial therapy and discusses education practices for newly diagnosed patients.

A panel of experts on HIV open the discussion with a conversation about the role of the primary care provider and advanced practice provider in treating patients with HIV.

A Centers for Disease Control and Prevention (CDC) investigator offers insights into their investigation of customers receiving vampire facials (a spa cosmetic procedure) and contracting the virus afterwards.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.

Study evaluates the outcomes of orthotopic liver transplantation of HIV-HBV coinfected patients.

New data shows young children are less likely to get diagnosed and get into the continuum of care including getting prescribed antiretroviral therapy (ART).

The CDC's take on the importance of HIV awareness and testing among our youth.

The federal agency has given the nod for dolutegravir/lamivudine (Dovato) for teens living with the virus and offers a novel option for patients.

Here is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.

The role of the US President’s Emergency Plan for AIDS Relief in combating tuberculosis (TB).

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Study proves the role of harnessing CrAgSQ for management over the infection.

The first-in-class entry inhibitor delivered therapeutic benefits over a long study period for patients with chronic infection.

Customizing treatment strategies for enhanced outcomes and longevity.

Defense against omicron in HIV-positive patients post-COVID.

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Unraveling monocyte activation and the implications for cardiovascular risk

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

A National Institutes of Health (NIH) sponsored study reveals a need for more accurate screening in Black people and cisgender women.

Study shows high efficacy of a 4-week glecaprevir/pibrentasvir regimen for shorter, more manageable treatment duration.

In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis